Role of Vasoactive Intestinal Peptide in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension

Lacedonia, Donato; ValerioGiuseppe,; Pia, PalladinoGrazia; Carpagnano, Giovanna Elisiana; Correale, Michele; Di, BiaseMatteo; Foschino, BarbaroMaria Pia

doi:10.1089/rej.2013.1478

Cited by 3 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In smoking COPD patients, increased expression of VIP was reported in the patients' epithelium, while it was downregulated in their airway smooth muscle cell layer as compared to smokers without COPD [22]. A similar increase in VIP was reported in arterial serum samples obtained from patients with COPD and pulmonary arterial hypertension (PAH) [23]. …”

Section: Introductionmentioning

confidence: 71%

Vasoactive Intestinal Peptide for Diagnosing Exacerbation in Chronic Obstructive Pulmonary Disease

et al. 2015

View full text Add to dashboard Cite

Background: Vasoactive intestinal peptide (VIP) is the most abundant neuropeptide in the lung. VIP has been linked to pulmonary arterial hypertension and hypoxia. Objectives: We aimed to assess circulating VIP levels at exacerbation and at stable chronic obstructive pulmonary disease (COPD) and to evaluate the diagnostic performance in a well-characterized cohort of COPD patients. Methods: The nested cohort study included patients with Global Initiative for Chronic Obstructive Lung Disease stage II-IV. Patients were examined at stable state and at acute exacerbation of COPD (AE-COPD), and dedicated serum was collected at both conditions. Serum VIP levels were determined by enzyme-linked immunosorbent assay. Diagnostic accuracy was analyzed by receiver operating characteristic curve and area under the curve (AUC). Results: Patients with acute exacerbation (n = 120) and stable COPD (n = 163) had similar characteristics at baseline. Serum VIP levels did not correlate with oxygen saturation at rest (p = 0.722) or at exercise (p = 0.168). Serum VIP levels were significantly higher at AE-COPD (130.25 pg/ml, 95% CI 112.19-151.83) as compared to stable COPD (40.07 pg/ml, 95% CI 37.13-43.96, p < 0.001). The association of increased serum VIP with AE-COPD remained significant after propensity score matching (p < 0.001). Analysis of the Youden index indicated the optimal serum VIP cutoff value as 56.6 pg/ml. The probability of AE-COPD was very low if serum VIP was ≤35 pg/ml (sensitivity >90%) and very high if serum VIP was ≥88 pg/ml (specificity >90%). Serum VIP levels presented a robust performance to diagnose AE-COPD (AUC 0.849, 95% CI 0.779-0.899). Conclusions: Increased serum VIP levels are associated with AE-COPD.

show abstract

Section: Introductionmentioning

confidence: 71%

Vasoactive Intestinal Peptide for Diagnosing Exacerbation in Chronic Obstructive Pulmonary Disease

et al. 2015

View full text Add to dashboard Cite

show abstract

“…As an important neuropeptide, VIP shows potent anti-inflammatory and immunomodulatory activities that affect both innate and adaptive immunity ( 40 ) and plays a critical role in the maintenance of the respiratory system homeostasis. Several animal and clinical trials suggest that VIP or VIP agonist treatment could be used for respiratory diseases, including acute lung injury, allergic asthma, and COPD ( 46 – 48 ). Our previous study showed that RSV-induced antiviral responses in KCF mice peak at 12 h postinfection, consistent with other research showing that IFN-α/β acts as a rapid-response cytokine upon RSV infection ( 49 ).…”

Section: Discussionmentioning

confidence: 99%

C-Fiber Degeneration Enhances Alveolar Macrophage-Mediated IFN-α/β Response to Respiratory Syncytial Virus

Wang

et al. 2022

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

“…Future research can be focused on the hypothesis that biomarkers can help clinicians to phenotype patients suffering from different forms of PH (e.g., interstitial lung disease, chronic obstructive pulmonary disease with PH [107,108], and advance HF with PH) and possibly direct them to specific drugs other than pulmonary vasodilators [109].…”

Section: Future Developmentsmentioning

confidence: 99%

Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update

Correale,

Tricarico,

Bevere

et al. 2024

Biomolecules

Self Cite

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is a rare subtype of group 1 pulmonary hypertension (PH) diseases, characterized by high pulmonary artery pressure leading to right ventricular dysfunction and potential life-threatening consequences. PAH involves complex mechanisms: vasoconstriction, vascular remodeling, endothelial dysfunction, inflammation, oxidative stress, fibrosis, RV remodeling, cellular hypoxia, metabolic imbalance, and thrombosis. These mechanisms are mediated by several pathways, involving molecules like nitric oxide and prostacyclin. PAH diagnosis requires clinical evaluation and right heart catheterization, confirming a value of mPAP ≥ 20 mmHg at rest and often elevated pulmonary vascular resistance (PVR). Even if an early and accurate diagnosis is crucial, PAH still lacks effective biomarkers to assist in its diagnosis and prognosis. Biomarkers could contribute to arousing clinical suspicion and serve for prognosis prediction, risk stratification, and dynamic monitoring in patients with PAH. The aim of the present review is to report the main novelties on new possible biomarkers for the diagnosis, prognosis, and treatment monitoring of PAH.

show abstract

Role of Vasoactive Intestinal Peptide in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension

Abstract: In the patients with COPD and PH and in particular in the group of OP PH, VIP is significantly increased, probably to correct the imbalance between vasoconstrictor and vasodilatator mediators.

Cited by 3 publications

References 24 publications

Vasoactive Intestinal Peptide for Diagnosing Exacerbation in Chronic Obstructive Pulmonary Disease

Vasoactive Intestinal Peptide for Diagnosing Exacerbation in Chronic Obstructive Pulmonary Disease

C-Fiber Degeneration Enhances Alveolar Macrophage-Mediated IFN-α/β Response to Respiratory Syncytial Virus

Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update

Contact Info

Product

Resources

About